Market Research Logo

Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2019

Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2019

Summary

This report provides an overview of the pipeline landscape for dermatological burns, scars and ulcers. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pressure ulcers, venous leg ulcers, burns and scars, and features dormant and discontinued products.

A pressure ulcer is an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition. There are six products in development for this indication.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of a finger when pressed (known as pitting edema), discoloration and darkening of the skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make the leg feel hard (known as lipodermatosclerosis), and small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche). There are 14 products in development for this indication.

A burn refers to damage to the body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, which increases with each degree of burn, red and swollen skin, blisters, and charred and blackened skin. Treatment includes antibiotics and pain relievers. There are 32 products in development for this indication.

A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red-to-purple fibrous tissue that over time usually becomes flatter and lighter in color. There are 20 products in development for this indication.

Molecular targets acted on by products in development for dermatological burns, scars and ulcers include integrins, interleukins and growth factors. Companies operating in this pipeline space include MediWound, Aegle Therapeutics and NovaLead Pharma.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons To Buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • Introduction
    • Dermatological Burns, Scars and Ulcers Report Coverage
    • Pressure Ulcers - Overview
    • Venous Leg Ulcers (Crural Ulcer) - Overview
    • Burns - Overview
    • Scar - Overview
    • Report Guidance
  • Therapeutics Development
    • Pressure Ulcers
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Pressure Ulcers
        • Table Number of Products under Development for Pressure Ulcers
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies, Pressure Ulcers
        • Table Number of Products under Development by Companies, Pressure Ulcers
      • Products under Development by Companies
        • Table Products under Development by Companies, Pressure Ulcers
    • Venous Leg Ulcers (Crural Ulcer)
      • Pipeline Overview
        • Table Figure 3: Number of Products under Development for Venous Leg Ulcers (Crural Ulcer)
        • Table Number of Products under Development for Venous Leg Ulcers (Crural Ulcer)
      • Pipeline by Companies
        • Table Figure 4: Number of Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer)
        • Table Number of Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer)
      • Products under Development by Companies
        • Table Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer)
    • Burns
      • Pipeline Overview
        • Table Figure 5: Number of Products under Development for Burns
        • Table Number of Products under Development for Burns
      • Pipeline by Companies
        • Table Figure 6: Number of Products under Development by Companies, Burns
        • Table Number of Products under Development by Companies, Burns
      • Pipeline by Universities/Institutes
        • Table Number of Products under Development by Universities/Institutes, Burns
      • Products under Development by Companies
        • Table Products under Development by Companies, Burns
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Burns
    • Scar
      • Pipeline Overview
        • Table Figure 7: Number of Products under Development for Scar
        • Table Number of Products under Development for Scar
      • Pipeline by Companies
        • Table Figure 8: Number of Products under Development by Companies, Scar
        • Table Number of Products under Development by Companies, Scar
      • Pipeline by Universities/Institutes
        • Table Figure 9: Number of Products under Development by Universities/Institutes, Scar
        • Table Number of Products under Development by Universities/Institutes, Scar
      • Products under Development by Companies
        • Table Products under Development by Companies, Scar
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Scar
  • Therapeutics Assessment
    • Pressure Ulcers
      • Assessment by Target
        • Table Figure 10: Number of Products by Stage and Targets, Pressure Ulcers
        • Table Number of Products by Stage and Target, Pressure Ulcers
      • Assessment by Mechanism of Action
        • Table Figure 11: Number of Products by Stage and Mechanism of Actions, Pressure Ulcers
        • Table Number of Products by Stage and Mechanism of Action, Pressure Ulcers
      • Assessment by Route of Administration
        • Table Figure 12: Number of Products by Routes of Administration, Pressure Ulcers
        • Table Figure 13: Number of Products by Stage and Routes of Administration, Pressure Ulcers
        • Table Number of Products by Stage and Route of Administration, Pressure Ulcers
      • Assessment by Molecule Type
        • Table Figure 14: Number of Products by Molecule Types, Pressure Ulcers
        • Table Figure 15: Number of Products by Stage and Molecule Types, Pressure Ulcers
        • Table Number of Products by Stage and Molecule Type, Pressure Ulcers
    • Venous Leg Ulcers (Crural Ulcer)
      • Assessment by Target
        • Table Figure 16: Number of Products by Top 10 Targets, Venous Leg Ulcers (Crural Ulcer)
        • Table Figure 17: Number of Products by Stage and Top 10 Targets, Venous Leg Ulcers (Crural Ulcer)
        • Table Number of Products by Stage and Target, Venous Leg Ulcers (Crural Ulcer)
      • Assessment by Mechanism of Action
        • Table Figure 18: Number of Products by Top 10 Mechanism of Actions, Venous Leg Ulcers (Crural Ulcer)
        • Table Figure 19: Number of Products by Stage and Top 10 Mechanism of Actions, Venous Leg Ulcers (Crural Ulcer)
        • Table Number of Products by Stage and Mechanism of Action, Venous Leg Ulcers (Crural Ulcer)
      • Assessment by Route of Administration
        • Table Figure 20: Number of Products by Routes of Administration, Venous Leg Ulcers (Crural Ulcer)
        • Table Figure 21: Number of Products by Stage and Top 10 Routes of Administration, Venous Leg Ulcers (Crural Ulcer)
        • Table Number of Products by Stage and Route of Administration, Venous Leg Ulcers (Crural Ulcer)
      • Assessment by Molecule Type
        • Table Figure 22: Number of Products by Molecule Types, Venous Leg Ulcers (Crural Ulcer)
        • Table Figure 23: Number of Products by Stage and Molecule Types, Venous Leg Ulcers (Crural Ulcer)
        • Table Number of Products by Stage and Molecule Type, Venous Leg Ulcers (Crural Ulcer)
    • Burns
      • Assessment by Target
        • Table Figure 24: Number of Products by Top 10 Targets, Burns
        • Table Figure 25: Number of Products by Stage and Top 10 Targets, Burns
        • Table Number of Products by Stage and Target, Burns
      • Assessment by Mechanism of Action
        • Table Figure 26: Number of Products by Top 10 Mechanism of Actions, Burns
        • Table Figure 27: Number of Products by Stage and Top 10 Mechanism of Actions, Burns
        • Table Number of Products by Stage and Mechanism of Action, Burns
      • Assessment by Route of Administration
        • Table Figure 28: Number of Products by Routes of Administration, Burns
        • Table Figure 29: Number of Products by Stage and Routes of Administration, Burns
        • Table Number of Products by Stage and Route of Administration, Burns
      • Assessment by Molecule Type
        • Table Figure 30: Number of Products by Molecule Types, Burns
        • Table Figure 31: Number of Products by Stage and Top 10 Molecule Types, Burns
        • Table Number of Products by Stage and Molecule Type, Burns
    • Scar
      • Assessment by Target
        • Table Figure 32: Number of Products by Top 10 Targets, Scar
        • Table Figure 33: Number of Products by Stage and Top 10 Targets, Scar
        • Table Number of Products by Stage and Target, Scar
      • Assessment by Mechanism of Action
        • Table Figure 34: Number of Products by Top 10 Mechanism of Actions, Scar
        • Table Figure 35: Number of Products by Stage and Top 10 Mechanism of Actions, Scar
        • Table Number of Products by Stage and Mechanism of Action, Scar
      • Assessment by Route of Administration
        • Table Figure 36: Number of Products by Routes of Administration, Scar
        • Table Figure 37: Number of Products by Stage and Routes of Administration, Scar
        • Table Number of Products by Stage and Route of Administration, Scar
      • Assessment by Molecule Type
        • Table Figure 38: Number of Products by Molecule Types, Scar
        • Table Figure 39: Number of Products by Stage and Molecule Types, Scar
        • Table Number of Products by Stage and Molecule Type, Scar
  • Companies Involved in Therapeutics Development
    • Pressure Ulcers
      • EyeGene Inc
        • Table Pressure Ulcers - Pipeline by EyeGene Inc
      • MimeTech Srl
        • Table Pressure Ulcers - Pipeline by MimeTech Srl
      • NovaLead Pharma Pvt Ltd
        • Table Pressure Ulcers - Pipeline by NovaLead Pharma Pvt Ltd
      • Shionogi & Co Ltd
        • Table Pressure Ulcers - Pipeline by Shionogi & Co Ltd
    • Venous Leg Ulcers (Crural Ulcer)
      • CardioVascular BioTherapeutics Inc
        • Table Venous Leg Ulcers (Crural Ulcer) - Pipeline by CardioVascular BioTherapeutics Inc
      • CytoTools AG
        • Table Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG
      • Daval International Ltd
        • Table Venous Leg Ulcers (Crural Ulcer) - Pipeline by Daval International Ltd
      • FirstString Research Inc
        • Table Venous Leg Ulcers (Crural Ulcer) - Pipeline by FirstString Research Inc
      • GangaGen Inc
        • Table Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Inc
      • MallInckrodt Plc
        • Table Venous Leg Ulcers (Crural Ulcer) - Pipeline by MallInckrodt Plc
      • MediWound Ltd
        • Table Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd
      • NovaLead Pharma Pvt Ltd
        • Table Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd
      • Promore Pharma AB
        • Table Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB
    • Burns
      • AlgiPharma AS
        • Table Burns - Pipeline by AlgiPharma AS
      • Alliance Pharma Plc
        • Table Burns - Pipeline by Alliance Pharma Plc
      • Amarantus Bioscience Holdings Inc
        • Table Burns - Pipeline by Amarantus Bioscience Holdings Inc
      • Anterogen Co Ltd
        • Table Burns - Pipeline by Anterogen Co Ltd\
      • CFM Pharma Holding BV
        • Table Burns - Pipeline by CFM Pharma Holding BV
      • Destiny Pharma Plc
        • Table Burns - Pipeline by Destiny Pharma Plc
      • Energenesis Biomedical Co Ltd
        • Table Burns - Pipeline by Energenesis Biomedical Co Ltd\
      • Madam Therapeutics BV
        • Table Burns - Pipeline by Madam Therapeutics BV
      • MallInckrodt Plc
        • Table Burns - Pipeline by MallInckrodt Plc
      • MediWound Ltd
        • Table Burns - Pipeline by MediWound Ltd
      • Phagelux Inc
        • Table Burns - Pipeline by Phagelux Inc
      • Se-cure Pharmaceuticals Ltd
        • Table Burns - Pipeline by Se-cure Pharmaceuticals Ltd
      • USV Pvt Ltd
        • Table Burns - Pipeline by USV Pvt Ltd
      • viDA Therapeutics Inc
        • Table Burns - Pipeline by viDA Therapeutics Inc
    • Scar
      • Abzena Plc
        • Table Scar - Pipeline by Abzena Plc
      • BirchBioMed Inc
        • Table Scar - Pipeline by BirchBioMed Inc
      • Cotinga Pharmaceuticals Inc
        • Table Scar - Pipeline by Cotinga Pharmaceuticals Inc
      • Kringle Pharma Inc
        • Table Scar - Pipeline by Kringle Pharma Inc
      • Moerae Matrix Inc
        • Table Scar - Pipeline by Moerae Matrix Inc
      • Pharmaxis Ltd
        • Table Scar - Pipeline by Pharmaxis Ltd
      • Phio Pharmaceuticals Corp
        • Table Scar - Pipeline by Phio Pharmaceuticals Corp
      • Promore Pharma AB
        • Table Scar - Pipeline by Promore Pharma AB
      • Resolys Bio Inc
        • Table Scar - Pipeline by Resolys Bio Inc
      • Synedgen Inc
        • Table Scar - Pipeline by Synedgen Inc
      • Vascular BioSciences
        • Table Scar - Pipeline by Vascular BioSciences
  • Dormant Projects
    • Pressure Ulcers
      • Table Pressure Ulcers - Dormant Projects
    • Venous Leg Ulcers (Crural Ulcer)
      • Table Venous Leg Ulcers (Crural Ulcer) - Dormant Projects
    • Burns
      • Table Burns - Dormant Projects
    • Scar
      • Table Scar - Dormant Projects
  • Discontinued Products
    • Pressure Ulcers
      • Table Pressure Ulcers - Discontinued Products
    • Venous Leg Ulcers (Crural Ulcer)
      • Table Venous Leg Ulcers (Crural Ulcer) - Discontinued Products
    • Burns
      • Table Burns - Discontinued Products
    • Scar
      • Table Scar - Discontinued Products
  • Product Development Milestones
    • Venous Leg Ulcers (Crural Ulcer)
      • Featured News & Press Releases
    • Burns
      • Featured News & Press Releases
    • Scar
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook